Cocrystal(US:COCP)2022-08-17 21:19Pipeline Highlights - Cocrystal Pharma is advancing COVID-19 and influenza programs, targeting large global markets for acute and pandemic viral diseases[7] - Planned Phase 1 trials in 2022 for COVID-19 oral protease inhibitor and CDI-45205 lead molecule[7, 8] - Influenza A CC-42344 (oral administration) Phase 1 results are expected in 2022, with a Phase 2a study expected to begin in 2023[7] - Preclinical lead selection for the Norovirus Gastroenteritis program is planned for 2022-2023[8] Collaboration and Technology - Merck collaboration for influenza A/B therapeutic validates Cocrystal's drug discovery platform technology, with potential for up to $156 million in milestone payments plus royalties[7, 28] - The company's proprietary drug discovery platform technology aims for viable drug candidates at reduced development timelines and costs[9, 11] Financial Status - As of June 30, 2022, Cocrystal Pharma had approximately $51 million in cash and equivalents[45] - The company has a clean balance sheet with no preferred shares or debt, and cash is sufficient to fund planned operations[7, 45] - The company's market capitalization is approximately $47 million[44] Market and Disease Overview - The global influenza therapeutics market is projected to reach $95 billion by 2027, growing at a 48% CAGR between 2021 and 2027[23] - Norovirus is responsible for approximately 685 million infections annually worldwide, costing an estimated $60 billion annually[31] - An estimated 58 million people worldwide have chronic hepatitis C virus infection, with about 15 million new infections occurring per year[36]